One engagement, both halves: a GMC-registered clinician for the safety case and the credibility, and a commercial operator for CQC, pricing and go-to-market reality — from a pair who already run a regulated UK clinic together.
Health-tech and healthcare companies entering or scaling in the UK normally hire two separate consultants: a clinician to review clinical safety and lend credibility, and a commercial adviser to navigate CQC and figure out how clinics actually buy. The two never speak. The result is products that are safe but commercially unviable — or commercially attractive but unsellable to any clinician who reads the risk log. We solve both halves in one contract, and because we run a regulated clinic together every week, our advice has already survived contact with reality.
A working clinical–commercial partnership — not two CVs stapled together.
GMC-registered GP and former surgeon; practising NHS GP partner; Clinical Director of a CQC-registered private clinic specialising in menopause and women's health.
Managing Director (non-clinical) of the same clinic — took it through CQC registration personally. Thirty years of P&L operations leadership and a daily agentic-AI practitioner.
Scoped up front, remote-first, sized to the stage you're at.
Fixed-scope project: clinical-risk posture, CQC/regulatory pathway, pricing and route-to-market for one product. Written findings + working session with both of us.
Monthly access to the pair: clinical-safety input as the product evolves, commercial guidance as the pipeline builds, both perspectives in the same conversation.
Board seats, investor due-diligence support and expert consultation — clinical and commercial views delivered together or separately as needed.
Both halves, one invoice. Published so you can budget before we speak.
| UK-entry readiness reviewclinical-risk posture, CQC/regulatory pathway, pricing and route to market for one product — written findings plus a working session with both of us | £4,500 |
| Standing advisory retainermonthly access to the pair — clinical safety input as the product evolves, commercial guidance as the pipeline builds | from £2,500/month |
| Advisory board — the pairper meeting, including preparation and follow-up note | £2,000 |
| Due-diligence supportfor investors assessing a UK healthcare or health-tech asset — clinical and commercial lenses in one report | £3,500 |
Equity-inclusive arrangements considered for early-stage companies. Either half is available separately at the rates published on our individual sites.